Burden of postmenopausal breast cancer attributable to excess body weight: comparative study of body mass index and CUN-BAE in MCC-Spain study.

BREAST NEOPLASMS HEALTH IMPACT ASSESSMENT OBESITY

Journal

Journal of epidemiology and community health
ISSN: 1470-2738
Titre abrégé: J Epidemiol Community Health
Pays: England
ID NLM: 7909766

Informations de publication

Date de publication:
17 Oct 2024
Historique:
received: 23 04 2023
accepted: 20 07 2024
medline: 18 10 2024
pubmed: 18 10 2024
entrez: 17 10 2024
Statut: aheadofprint

Résumé

10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.

Sections du résumé

BACKGROUND BACKGROUND
10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE.
METHODS METHODS
This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type.
RESULTS RESULTS
Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m
CONCLUSION CONCLUSIONS
These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.

Identifiants

pubmed: 39419524
pii: jech-2023-220706
doi: 10.1136/jech-2023-220706
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Naiara Cubelos-Fernández (N)

Gene-Environment Interactions and Health Research Group (GIIGAS), University of León Institute of Biomedicine, Leon, Spain.
Gerencia de Atencion Primaria, Área de Salud de Valladolid, Valladolid, Spain.

Verónica Dávila-Batista (V)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain veronica.davila@ulpgc.es.
Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Tania Fernández-Villa (T)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Gene-Environment Interactions and Health Research Group (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, Leon, Spain.

Gemma Castaño-Vinyals (G)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.

Beatriz Perez-Gomez (B)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Department of Chronic Disease Epidemiology, National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.

Pilar Amiano (P)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, Donostia-san Sebastian, Spain.
Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, Donostia-san Sebastian, Spain.

Eva Ardanaz (E)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Instituto de Salud Pública y Laboral de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

Irene Delgado Sillero (I)

Gene-Environment Interactions and Health Research Group (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, Leon, Spain.

Javier Llorca (J)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Universidad de Cantabria, Santander, Spain.

Guillermo Fernández Tardón (GF)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
ISPA, Health Research Institute of the Principality of Asturias, Oviedo, Spain.

Juan Alguacil (J)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Natural Resources, Health and Environment Research Centre (RENSMA), Universidad de Huelva-Campus El Carmen, Huelva, Spain.

Mercedes Vanaclocha Espí (M)

Cancer and Public Health, FISABIO, Valencia, Spain.

Rafael Marcos-Gragera (R)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology Girona, University of Girona, Girona, Spain.
Descriptive Epidemiology, Genetics and Cancer Prevention Group, Institute of Biomedical Research of Girona Dr Josep Trueta (IDIBGI-CERCA), Girona, Spain.

Víctor Moreno (V)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.
Colorectal Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain.

Nuria Aragones (N)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Public Health Division, Department of Health of Madrid, Madrid, Spain.

Ane Dorronsoro (A)

Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, Donosti-San Sebastian, Spain.

Marcela Guevara (M)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Instituto de Salud Pública y Laboral de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

Sofía Reguero Celada (S)

Gerencia de Atencion Primaria, Área de Salud de León, Leon, Spain.

Marina Pollan (M)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Department of Chronic Disease Epidemiology, National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.

Manolis Kogevinas (M)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.

Vicente Martín (V)

Consortium for Biomedical Research in Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Gene-Environment Interactions and Health Research Group (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, Leon, Spain.

Classifications MeSH